Bio Usawa and Nanoly Bioscience have signed a significant licensing agreement for the DynaShieldTM technology, valued at up to $500 million. This partnership grants Bio Usawa exclusive worldwide rights to utilize and sublicense the DynaShieldTM technology across its product line and third-party biologics and vaccines, facilitating widespread commercial deployment across various therapeutic platforms.
The DynaShieldTM technology addresses a critical issue in the biopharmaceutical industry: the reliance on the “cold chain” for transporting and storing biologics. This specialized, temperature-controlled supply chain is often fragile, costly, and inaccessible in many regions, particularly in underserved markets. By employing a unique polymer scaffold, DynaShieldTM shields sensitive proteins from thermal degradation, allowing essential medical products to remain stable outside refrigeration for extended periods.
Dr. Menghis Bairu, CEO of Bio Usawa, emphasized the importance of this technology in enhancing health equity. “Our mission is to make biologics affordable and accessible,” he stated. “By eliminating the cold chain requirement through this technology, we are removing the single greatest logistical barrier to health equity. This $500 million investment reflects our confidence that this technology will redefine global drug access.”
Dr. Balaji Sridhar, CEO of Nanoly Bioscience, added that Bio Usawa is the right partner to advance DynaShieldTM on a global scale. “Their manufacturing scale and commitment to underserved markets align perfectly with our vision of a world where access to life-saving medicine isn’t limited by the reach of a refrigerator,” he noted.
Transforming Global Health Outcomes
This collaboration is poised to significantly reduce the overhead costs associated with the distribution of biologics and vaccines. According to the World Health Organization, up to 50 percent of vaccines are wasted globally each year due to failures in the cold chain, logistics breakdowns, and temperature control issues. In financial terms, industry analyses estimate that cold-chain temperature excursions and logistics failures cost the biopharmaceutical sector between $20 billion and $35 billion annually in spoiled products, reshipment costs, and compliance losses.
By enabling room-temperature stability, DynaShieldTM has the potential to drastically lower vaccine and biologic wastage rates. This innovation not only reduces distribution costs but also expands access to life-saving therapies worldwide, especially in areas where controlled refrigeration infrastructure is limited.
About the Companies
Bio Usawa is dedicated to the manufacturing and distribution of high-quality biosimilars and essential biologics. With a focus on emerging markets, the company aims to bridge healthcare accessibility gaps through innovation and localized production.
Nanoly Bioscience specializes in the stabilization of high-value biologics. The DynaShieldTM platform is specifically designed to protect biologics from temperature fluctuations, ensuring their efficacy from the point of manufacture to the point of care.
For further information, media inquiries can be directed to the press office at Bio Usawa via email at [email protected] or by calling +1 (555) 012-3456. Investor relations can be contacted at [email protected].
